Biotech vets launch a neuro startup with $54.5M to kickstart R&D
More than 2 years after Kathleen Sereda Glaub and Anthony Ford helped line up a $1.25 billion deal to sell Afferent Pharmaceuticals to Merck, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
